Research goal
Wound Healing & Tissue Repair
Covers peptides researched in the context of wound healing, post-surgical recovery, chronic wound management, and tissue repair: angiogenesis, ECM remodelling, antimicrobial defence, and re-epithelialisation. Distinct from the Recovery & Healing goal, which targets sports injuries and musculoskeletal repair. All content is educational reference for researchers; no compound on this page is approved as a wound healing drug.
Relevant Compounds
| Compound | Class | Primary mechanism | Commonly reported for | Link |
|---|---|---|---|---|
| BPC-157 | Pentadecapeptide / cytoprotective | Angiogenesis via VEGFR2; nitric oxide pathway; re-epithelialisation; anti-inflammatory; tendon and gut mucosal repair | Wound healing, tendon repair, post-surgical tissue healing, anti-inflammatory | View profile → |
| GHK-Cu | Copper tripeptide | Fibroblast activation; collagen and glycosaminoglycan synthesis; wound contraction; ECM remodelling; anti-inflammatory | Wound healing, skin repair, collagen synthesis, scar remodelling | View profile → |
| TB-500 | Thymosin Beta-4 fragment | G-actin sequestration; systemic cell migration; angiogenesis; anti-inflammatory; promotes tissue repair beyond injection site | Tissue repair, wound healing, systemic angiogenesis, anti-inflammatory | View profile → |
| LL-37 | Cathelicidin host defence peptide | Broad-spectrum antimicrobial; keratinocyte migration; angiogenesis; biofilm disruption; immune modulation | Chronic wounds, infected wounds, antimicrobial wound bed preparation, re-epithelialisation | View profile → |
| Collagen Peptides | Hydrolysed collagen | Provides collagen synthesis substrates; osteoblast and fibroblast stimulation; ECM support via bioactive collagen fragments | Post-surgical recovery support, wound nutrition, structural collagen | View profile → |
| AHK-Cu | Copper tripeptide (alanyl-histidyl-lysine) | ECM remodelling; angiogenesis; anti-apoptotic; collagen and elastin synthesis; wound bed vascularisation | Wound repair, scar remodelling, skin healing, anti-fibrotic research | View profile → |
Research Context
Wound healing is a complex, highly coordinated biological process involving four overlapping phases: haemostasis, inflammation, proliferation, and remodelling. Each phase requires precise timing and molecular coordination to progress to the next: premature or incomplete resolution of inflammation prevents proliferative phase entry; insufficient angiogenesis during proliferation impairs oxygen and nutrient delivery to regenerating tissue; failed ECM remodelling in the final phase produces fibrotic scarring rather than functional tissue restoration. Chronic wounds, including diabetic ulcers, venous leg ulcers, pressure injuries, and non-healing post-surgical wounds, are characterised by disruption of this progression, typically stalling in a sustained inflammatory state. They represent one of the most significant unmet needs in clinical medicine, affecting tens of millions of patients globally with disproportionate burden in populations with diabetes, vascular disease, and advanced age. Peptide research in wound healing targets multiple phases simultaneously, particularly angiogenesis and vascularisation, inflammation resolution, fibroblast and ECM activation, antimicrobial defence in contaminated wounds, and re-epithelialisation.
BPC-157 (body protective compound 157) is the most extensively studied peptide in the wound healing research context, with a substantial animal model evidence base covering cutaneous wound healing, tendon repair, ligament repair, muscle injury, gut mucosal healing, and bone repair. Its primary wound healing mechanisms operate through VEGFR2-mediated angiogenesis, nitric oxide pathway modulation, and stimulation of growth factor expression including VEGF and EGF. Multiple rodent studies have demonstrated accelerated wound closure, improved tensile strength in healing tendons, and accelerated re-epithelialisation compared to controls. BPC-157 remains in preclinical stages in Western regulatory frameworks and has not completed large-scale human clinical trials for wound indications, though investigational use in human research communities is documented.
GHK-Cu and AHK-Cu are copper tripeptides with documented roles in wound healing biology. GHK-Cu occurs naturally in human plasma and declines significantly with age. Research has demonstrated its capacity to activate fibroblasts, stimulate collagen type I and III synthesis, promote glycosaminoglycan production, accelerate wound contraction, and modulate anti-inflammatory gene expression. It has been investigated both topically for cutaneous wound healing and subcutaneously for systemic tissue effects. AHK-Cu shares ECM remodelling and angiogenic properties with GHK-Cu but has a more targeted mechanism relevant to dermal papilla cells and skin healing, with additional anti-apoptotic and anti-fibrotic properties that are relevant to scar remodelling in post-wound tissue.
TB-500, a synthetic fragment of thymosin beta-4, promotes wound healing through a mechanism distinct from BPC-157 and the copper peptides: G-actin sequestration promotes cell motility and migration across tissue types, and its angiogenic effects operate systemically rather than only at the injection site. This systemic mechanism makes TB-500 particularly relevant for wound healing in contexts where the defect spans a large area or where systemic tissue repair capacity is important. BPC-157 and TB-500 are frequently combined in the Wolverine stack, where their complementary mechanisms provide additive support for tissue repair, with BPC-157 contributing localised healing and nitric oxide pathway effects alongside TB-500's systemic cell migration and angiogenic activity.
LL-37 occupies a distinct niche within wound healing peptide research as the only compound on this page with direct antimicrobial activity. As the sole human cathelicidin, LL-37 is produced by keratinocytes, neutrophils, and macrophages at wound sites and functions as a first-line defence against bacterial contamination. It disrupts bacterial membranes through membrane-permeabilising mechanisms and inhibits biofilm formation, a critical challenge in chronic wounds where established biofilms render conventional antibiotic therapy ineffective. Beyond its antimicrobial role, LL-37 promotes keratinocyte migration and proliferation, stimulates angiogenesis, and modulates the inflammatory response to support healing. Its dual antimicrobial and wound-promoting mechanism makes it a compound of particular interest for diabetic ulcers and venous leg ulcers, where bacterial contamination and impaired healing biology co-exist. LL-37 is under active clinical investigation for chronic wound applications.
This goal page is distinct from the Recovery & Healing goal, which targets sports injuries, musculoskeletal repair, and athlete recovery. Several compounds appear on both pages, particularly BPC-157 and TB-500, because their mechanisms are relevant across multiple wound and injury types. The clinical populations, research contexts, and therapeutic applications differ substantially: wound healing research addresses post-surgical wounds, chronic wounds, diabetic ulcers, pressure injuries, and burn injuries, while recovery research addresses tendon tears, muscle strains, ligament damage, and performance recovery. Researchers interested in sports injury contexts should consult the Recovery & Healing goal page.
Key Research Areas
Angiogenesis & Vascularisation
New blood vessel formation is essential for the delivery of oxygen, nutrients, and immune cells to regenerating wound tissue. Impaired angiogenesis is a central mechanism underlying the chronicity of diabetic ulcers and other non-healing wounds, where microvascular disease reduces the neovascularisation response. BPC-157 stimulates VEGFR2 and promotes neovascularisation; multiple animal studies have documented increased vessel density in BPC-157-treated wounds. TB-500 promotes angiogenesis through actin modulation and cell migration pathways that are partly independent of VEGF signalling. GHK-Cu upregulates VEGF and other pro-angiogenic growth factors as part of its broad gene regulatory effects. AHK-Cu has documented angiogenic and anti-apoptotic effects on endothelial cells relevant to wound bed vascularisation. The multi-compound angiogenic activity profile of this category is a feature distinguishing peptide research from single-target pharmaceutical approaches.
Fibroblast Activation & Collagen Synthesis
The proliferative phase of wound healing depends on fibroblast migration into the wound bed, synthesis of collagen and other ECM components, and wound contraction. GHK-Cu is the primary compound on this page for fibroblast activation, with multiple published studies documenting stimulation of collagen types I and III, glycosaminoglycan synthesis, and activation of genes associated with tissue remodelling. AHK-Cu contributes complementary ECM remodelling and anti-fibrotic properties that may be particularly relevant in scar remodelling during the final maturation phase. Collagen peptides, through oral supplementation, provide bioactive collagen fragments that stimulate fibroblast collagen synthesis and serve as structural substrate, with human randomised controlled trial data supporting their efficacy for skin collagen and bone mineral density outcomes relevant to wound healing nutritional support.
Antimicrobial Defence & Immune Modulation
Chronic and contaminated wounds present antimicrobial challenges that exceed the capacity of mechanical debridement alone, particularly where biofilm formation has established a protective matrix that shields bacteria from systemic antibiotic penetration. LL-37 addresses this challenge through direct membrane-permeabilising antimicrobial activity against both gram-positive and gram-negative pathogens, biofilm disruption, and simultaneous immune modulation that supports the transition from inflammatory to reparative wound biology. Its dual antimicrobial and wound-promoting profile is distinct from conventional antibiotics, which address infection without contributing to healing mechanisms. Research programmes investigating LL-37 for diabetic ulcers and venous leg ulcers have advanced to clinical phase trials, reflecting this unique dual-function rationale for wound healing applications.
Cell Migration & Re-epithelialisation
Re-epithelialisation, the migration of keratinocytes across the wound surface to restore the epidermal barrier, is a critical determinant of wound closure in cutaneous wounds. BPC-157 has been documented to promote re-epithelialisation and accelerate wound closure in animal models through growth factor pathway activation. LL-37 directly stimulates keratinocyte migration, a property that is well-characterised in cathelicidin biology and contributes to its wound healing activity beyond its antimicrobial function. TB-500 acts on actin polymerisation and depolymerisation dynamics in a way that promotes cell motility across tissue types, including keratinocytes and endothelial cells, supporting both re-epithelialisation and angiogenic cell migration simultaneously. The complementary cell migration mechanisms of BPC-157, LL-37, and TB-500 across these different cellular targets represent a research rationale for multi-compound wound healing protocols.
Anti-inflammatory Resolution
The inflammatory phase of wound healing is necessary for pathogen clearance and wound bed preparation, but must resolve in a timely manner to allow progression to the proliferative phase. Chronic wounds are characterised by persistent inflammation, elevated proteases, and sustained cytokine signalling that prevents this progression and degrades the ECM and growth factors needed for repair. BPC-157 modulates pro-inflammatory cytokine production and promotes nitric oxide-mediated vascular and tissue responses that support resolution. GHK-Cu has documented anti-inflammatory gene regulation effects, reducing NF-kB pathway activity and inflammatory cytokine expression while promoting tissue repair gene upregulation. TB-500 reduces pro-inflammatory cytokines including tumour necrosis factor-alpha and interleukin-1 beta in animal wound models. The concerted anti-inflammatory mechanisms of these compounds across different molecular targets provide a rationale for their potential utility in chronically inflamed wound environments.
Compound Notes
BPC-157
BPC-157 is a 15-amino acid synthetic peptide derived from a body protective compound isolated from human gastric juice. Its wound healing research base is among the most extensive of any investigational peptide, with published animal studies across cutaneous wounds, tendon and ligament tears, muscle injuries, bone repair, and gut mucosal damage. The primary mechanisms include stimulation of VEGF and VEGFR2-mediated neovascularisation, activation of the nitric oxide pathway supporting vascular and anti-inflammatory responses, promotion of growth factor expression including EGF, and direct cytoprotective effects on stressed tissue. BPC-157 can be administered subcutaneously near the wound site or systemically, with research supporting efficacy via both routes. It remains in preclinical regulatory status in Western markets, without phase III trial data for wound healing indications. It is not a prohibited substance under WADA regulations.
GHK-Cu
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine at concentrations that decline substantially with age. In wound healing contexts, GHK-Cu has been investigated for its fibroblast-activating and collagen-stimulating properties since early research by Loren Pickart demonstrating regenerative activity in liver tissue. Published research has documented stimulation of collagen types I and III, glycosaminoglycan synthesis, and wound contraction in dermal models. It upregulates pro-repair genes through mechanisms involving TGF-beta signalling and transcription factor activation. GHK-Cu is available topically in cosmetic formulations at concentrations of 0.01 to 0.1 percent, and is administered subcutaneously in research protocols at 1 to 2 mg doses. Both routes have documented effects on wound healing parameters in the published literature.
TB-500
TB-500 is a synthetic analogue of the C-terminal region of thymosin beta-4, a naturally occurring actin-binding protein. Its primary wound healing mechanism is G-actin sequestration, which regulates the ratio of monomeric to filamentous actin in cells and promotes cell motility by modulating actin dynamics at the cell membrane. This mechanism drives migration of keratinocytes, fibroblasts, endothelial cells, and smooth muscle cells, supporting re-epithelialisation, angiogenesis, and wound bed preparation. Animal studies have documented accelerated wound closure, increased collagen deposition, and improved tensile strength in TB-500-treated wounds. Unlike BPC-157, TB-500's mechanism operates primarily through cytoskeletal dynamics rather than receptor signalling, making the two compounds mechanistically complementary. TB-500 is prohibited by WADA and is not suitable for athletes subject to anti-doping regulations. It is not approved as a wound healing agent.
LL-37
LL-37 is the sole human cathelicidin, a class of host defence peptides produced as part of the innate immune response. It is generated from the precursor protein hCAP18, which is cleaved to release the active LL-37 peptide at sites of infection and tissue damage. Its 37-amino acid amphipathic alpha-helical structure enables it to disrupt bacterial membranes through membrane-permeabilising mechanisms effective against gram-positive bacteria, gram-negative bacteria, and fungi, in addition to disrupting the polysaccharide matrix of bacterial biofilms. In parallel with its antimicrobial function, LL-37 directly promotes wound healing: it stimulates keratinocyte migration and proliferation via EGF receptor transactivation, promotes angiogenesis, and modulates the innate immune response to support resolution of inflammation. Multiple clinical research programmes are investigating synthetic LL-37 preparations for diabetic foot ulcers and venous leg ulcers, where its antimicrobial and wound-healing dual function offers a unique therapeutic rationale.
Collagen Peptides
Collagen peptides (hydrolysed collagen) are orally administered small collagen-derived fragments produced by enzymatic hydrolysis of native collagen. They are absorbed intact in the gastrointestinal tract and accumulate in skin and connective tissue, where they stimulate fibroblast collagen synthesis via mechanisms involving bioactive dipeptide and tripeptide fragments. In wound healing contexts, collagen peptides are relevant primarily as a nutritional adjunct that supports the protein substrate requirements of the proliferative and remodelling phases. Clinical studies in populations with skin wounds and post-surgical recovery have reported improved wound closure rates and collagen density outcomes with oral collagen peptide supplementation at 5 to 10 g per day. A randomised controlled trial in postmenopausal women documented significant increases in bone mineral density with specific collagen peptide supplementation, relevant to the bone repair context. Collagen peptides are classified as food supplements, are widely available without prescription, and are well-tolerated across multiple clinical trials, making them a low-barrier adjunct to other compounds on this page.
AHK-Cu
AHK-Cu (alanyl-histidyl-lysine copper complex) is a copper tripeptide related to GHK-Cu but with distinct structural properties that confer a more targeted mechanism relevant to dermal papilla cells and certain skin wound repair contexts. AHK-Cu has been investigated for ECM remodelling, angiogenesis, and anti-apoptotic effects in skin tissue research. Its anti-fibrotic properties are of particular interest in the context of scar remodelling: where GHK-Cu primarily drives collagen synthesis and wound contraction, AHK-Cu's anti-apoptotic and remodelling effects may be complementary during the maturation phase when excessive fibrosis and scar formation are clinical concerns. Published research has investigated AHK-Cu in both dermal papilla and cutaneous wound contexts. In wound healing protocols, AHK-Cu is typically used topically alongside GHK-Cu rather than as a standalone wound healing agent. It is available in topical formulations; subcutaneous use is less commonly described in the wound healing literature compared to its hair and scalp research context. See the GHK-Cu vs AHK-Cu comparison for a detailed mechanism breakdown.
Regulatory Note
No peptide on this page is currently FDA-approved as a wound healing drug. BPC-157 and MOTS-c remain investigational without approved formulations in Western markets. TB-500 is prohibited by WADA and its research use in athletes subject to anti-doping regulations is not appropriate. LL-37 is under clinical investigation for chronic wound indications; no approved formulation is currently available. GHK-Cu and AHK-Cu are available topically in cosmetic formulations; their subcutaneous or pharmaceutical wound healing use is not approved and is investigational. Collagen peptides are classified as food supplements and are not regulated as wound healing drugs. This page is an educational research reference and does not constitute medical advice. Post-surgical or chronic wound management should be conducted under qualified clinical supervision.
Frequently Asked Questions
Which peptides are researched for wound healing?
BPC-157, GHK-Cu, TB-500, LL-37, AHK-Cu, and Collagen Peptides have all been investigated for wound healing and tissue repair. BPC-157 has the most extensive animal model evidence base. GHK-Cu is the primary fibroblast-activating and collagen-stimulating compound. TB-500 provides systemic cell migration and angiogenic support. LL-37 uniquely combines antimicrobial activity with wound-promoting effects. AHK-Cu contributes ECM remodelling and anti-fibrotic properties. Collagen peptides support wound nutritional substrate provision. None are approved as wound healing drugs in Western markets.
Is BPC-157 effective for wound healing?
BPC-157 has demonstrated consistent wound healing effects in animal model research across multiple wound types, including cutaneous wounds, tendon injuries, ligament tears, and gut mucosal damage. The animal evidence base is substantial. However, BPC-157 has not completed phase III clinical trials for wound healing indications and remains in preclinical regulatory status in Western markets. The translation of its animal model results to human wound healing is under investigation. Its use in this context is investigational.
What peptides help with chronic wounds?
Chronic wounds are characterised by sustained inflammation and failure to progress through normal healing phases, often complicated by infection and biofilm formation. LL-37 is particularly relevant for its combined antimicrobial and wound-promoting properties, with clinical research programmes investigating it for diabetic foot ulcers and venous leg ulcers. BPC-157 addresses the angiogenic deficit and inflammatory dysregulation common in chronic wounds. GHK-Cu supports ECM remodelling and fibroblast activation. None are currently approved as chronic wound therapies.
Can peptides help with post-surgical recovery?
Post-surgical wound healing engages all four wound healing phases. BPC-157 has been studied for soft tissue repair acceleration in animal models relevant to surgical healing. Collagen peptides support structural collagen provision during the remodelling phase with human clinical data. GHK-Cu supports collagen synthesis and wound contraction. TB-500 promotes systemic cell migration and repair. All use in post-surgical contexts is investigational; clinical wound care should involve qualified surgical and nursing supervision regardless of any supplementary research compound use.
What is the difference between BPC-157 and TB-500 for wound healing?
BPC-157 and TB-500 have complementary mechanisms. BPC-157 acts primarily through VEGFR2-mediated angiogenesis, nitric oxide pathway modulation, and growth factor signalling, with documented effects on localised wound healing and tendon, ligament, and gut mucosal repair. TB-500 acts via G-actin sequestration to promote systemic cell migration and angiogenesis beyond the immediate injury site. BPC-157 is often described as more targeted to specific wound sites; TB-500's systemic mechanism supports broader tissue repair. They are frequently combined in the Wolverine stack for additive tissue repair support, with their complementary mechanisms addressing different cellular and vascular targets simultaneously.